PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
17082756-3	2007	In this analysis, adjusted mean serum 25-hydroxyvitamin D was significantly lower only in the participants with a severe (15-29 ml/min/1.73 m(2)) decrease in eGFR compared to those with normal kidney function (61.6 vs 73.3 nmol/l, P=0.0063).	25-hydroxyvitamin D	38-57	epidermal growth factor receptor	Homo sapiens	158-162	
25901090-3	2015	This study evaluated the association of serum 25-hydroxyvitamin D with change in eGFR, rapid eGFR decline, and incidence of CKD and albuminuria.	25-hydroxyvitamin D	46-65	epidermal growth factor receptor	Homo sapiens	81-85	
25901090-9	2015	Before adjustment for baseline eGFR, baseline 25-hydroxyvitamin D level was associated with both mean annual eGFR change and risk of rapid eGFR decline, independently of baseline albuminuria.	25-hydroxyvitamin D	46-65	epidermal growth factor receptor	Homo sapiens	31-35	
25901090-9	2015	Before adjustment for baseline eGFR, baseline 25-hydroxyvitamin D level was associated with both mean annual eGFR change and risk of rapid eGFR decline, independently of baseline albuminuria.	25-hydroxyvitamin D	46-65	epidermal growth factor receptor	Homo sapiens	109-113	
25901090-9	2015	Before adjustment for baseline eGFR, baseline 25-hydroxyvitamin D level was associated with both mean annual eGFR change and risk of rapid eGFR decline, independently of baseline albuminuria.	25-hydroxyvitamin D	46-65	epidermal growth factor receptor	Homo sapiens	109-113	
25901090-11	2015	For every 10 ng/ml higher baseline 25-hydroxyvitamin D, the adjusted mean annual eGFR change was -0.005 ml/min per 1.73 m(2) (95% confidence interval, -0.063 to 0.053; P=0.87) and the risk of rapid eGFR decline was null (odds ratio, 0.93; 95% confidence interval, 0.79 to 1.08; P=0.33).	25-hydroxyvitamin D	35-54	epidermal growth factor receptor	Homo sapiens	81-85	
25901090-11	2015	For every 10 ng/ml higher baseline 25-hydroxyvitamin D, the adjusted mean annual eGFR change was -0.005 ml/min per 1.73 m(2) (95% confidence interval, -0.063 to 0.053; P=0.87) and the risk of rapid eGFR decline was null (odds ratio, 0.93; 95% confidence interval, 0.79 to 1.08; P=0.33).	25-hydroxyvitamin D	35-54	epidermal growth factor receptor	Homo sapiens	198-202	
25901090-13	2015	CONCLUSIONS: The association of 25-hydroxyvitamin D with eGFR decline is confounded by baseline eGFR.	25-hydroxyvitamin D	32-51	epidermal growth factor receptor	Homo sapiens	57-61	
25901090-13	2015	CONCLUSIONS: The association of 25-hydroxyvitamin D with eGFR decline is confounded by baseline eGFR.	25-hydroxyvitamin D	32-51	epidermal growth factor receptor	Homo sapiens	96-100	
25030993-0	2014	Serum 25-hydroxyvitamin D levels correlate with EGFR mutational status in pulmonary adenocarcinoma.	25-hydroxyvitamin D	6-25	epidermal growth factor receptor	Homo sapiens	48-52	
22551881-6	2012	Both active regimens vs. placebo markedly increased serum 25-hydroxyvitamin D levels from baseline in all eGFR groups (p 0.22 for all time points).	25-hydroxyvitamin D	58-77	epidermal growth factor receptor	Homo sapiens	106-110	
33115916-0	2021	Differences in 25-Hydroxyvitamin D Clearance by eGFR and Race: A Pharmacokinetic Study.	25-hydroxyvitamin D	15-34	epidermal growth factor receptor	Homo sapiens	48-52	
34362787-1	2021	BACKGROUND AND OBJECTIVES: Low serum 25-hydroxyvitamin D (25(OH)D) concentration has been associated with higher levels of proteinuria and lower levels of eGFR in observational studies.	25-hydroxyvitamin D	37-56	epidermal growth factor receptor	Homo sapiens	155-159	
30646860-5	2019	Cox proportional risk model was used to evaluate associations between serum 25-Hydroxyvitamin D and CKD (including both albuminuria and impaired eGFR) incidence after adjusted for potential confounding..	25-hydroxyvitamin D	76-95	epidermal growth factor receptor	Homo sapiens	145-149